Publications by authors named "S D Esposti"
Article Synopsis
- The study investigates the long-term safety and efficacy of lenadogene nolparvovec, a gene therapy for Leber hereditary optic neuropathy (LHON) caused by the MT-ND4 gene variant, enrolling patients for up to 5 years after treatment.
- Conducted between 2018 and 2022, the RESTORE trial followed patients who previously participated in two phase 3 studies, RESCUE and REVERSE, focusing on vision loss treatment; most participants were male with an average age of 35.9 years.
- Results indicated that 94.7% of participants completed the initial studies, and 72.4% completed the 5-year follow-up, with key outcomes
Background: Art. 50 of the proposal for a Regulation on the European Health Data Space (EHDS) states that "health data access bodies shall provide access to electronic health data only through a secure processing environment, with technical and organizational measures and security and interoperability requirements".
Objective: To identify specific security measures that nodes participating in health data spaces shall implement based on the results of the IMPaCT-Data project, whose goal is to facilitate the exchange of electronic health records (EHR) between public entities based in Spain and the secondary use of this information for precision medicine research in compliance with the General Data Protection Regulation (GDPR).
Article Synopsis
- - In the DREAMM-2 study, belantamab mafodotin showed significant effectiveness and a manageable safety profile for patients with relapsed/refractory multiple myeloma (RRMM), particularly those who had failed multiple previous treatments.
- - Patient-reported outcomes (PROs) indicated that while some patients experienced ocular symptoms (like difficulties with vision, driving, and reading), these symptoms improved over time with recovery times ranging from 23.5 to 44 days.
- - Overall health-related quality of life (HRQOL) and core symptoms of multiple myeloma, including fatigue and pain, were maintained during treatment, supporting the use of belantamab mafodotin in RRMM patients and suggesting potential for